ArticleViruses2018
Characterization of vB_Kpn_F48, a Newly Discovered Lytic Bacteriophage for Klebsiella pneumoniae of Sequence Type 101.
Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Harnessing lytic phages for biofilm control in carbapenem-resistantMicrobiology spectrum · 2026Article
- Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, characterization, and genomic analysis of phage MY02 targeting extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.Archives of virology · 2025Article
- Characterizing the bacteriophage PKp-V1 as a potential treatment for ESBL-producing hypervirulent K1Veterinary world · 2024Article
- The potential use of bacteriophages as antibacterial agents against Klebsiella pneumoniae.Virology journal · 2024Review
- Benefits and Challenges of Applying Bacteriophage Biocontrol in the Consumer Water Cycle.Microorganisms · 2024Review
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- High activity and specificity of bacteriophage cocktails against carbapenem-resistantFrontiers in microbiology · 2024Article
- Phage P2-71 against multi-drug resistantFrontiers in cellular and infection microbiology · 2024Article
- Characterization of bacteriophage vB_KleM_KB2 possessing high control ability to pathogenic Klebsiella pneumoniae.Scientific reports · 2023Article
- Resistance ofMicrobiology spectrum · 2023Article
- Isolation, Partial Characterization and Application of Bacteriophages in Eradicating Biofilm Formation byPathogens (Basel, Switzerland) · 2022Article
- Characterization and Genomic Analysis of NovelViruses · 2022Article
- In Vitro and In Vivo Assessments of Two Newly Isolated Bacteriophages against an ST13 Urinary Tract InfectionViruses · 2022Article
- Characterization ofFrontiers in microbiology · 2022Article
- Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Review
- Nanobiosystems for Antimicrobial Drug-Resistant Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- Phage Resistance Is Associated with Decreased Virulence in KPC-ProducingMicroorganisms · 2021Article
- Strategy for mass production of lytic Staphylococcus aureus bacteriophage pSa-3: contribution of multiplicity of infection and response surface methodology.Microbial cell factories · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to carbapenems in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.